CureVac is currently undergoing a strategic acquisition by BioNTech to strengthen their capabilities in mRNA technology, aiming to enhance their therapeutic offerings in oncology and other medical fields.
Target Information
CureVac N.V. (Nasdaq: CVAC), a multinational biotech company headquartered in Tübingen, Germany, focuses on developing a new class of transformative medicines utilizing messenger RNA (mRNA) technology. Founded in 2000, CureVac has made significant advancements in mRNA capabilities, particularly in the context of COVID-19 vaccine development. Currently, the company is refocusing its efforts on cancer immunotherapy treatments, leveraging mRNA technology combined with innovative computational tools.
As of September 30, 2025, CureVac reported a robust cash position of €416.1 million, which is anticipated to sustain its operational activities into 2028. The company is currently undergoing a major transaction with BioNTech, which aims to consolidate both companies' expertise in mRNA technology and enhance their therapeutic offerings.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The biotechnology sector in Germany is highly regarded for its innovative research and development in medical technologies, particularly in the field of mRNA treatment. As the pioneer of mRNA vaccines, Germany has established itself as a leader,
Similar Deals
Teleflex Incorporated → Vaskuläre Intervention (VI) business unit of BIOTRONIK
2025
BioNTech
invested in
CureVac
in 2025
in a Merger deal
Disclosed details
Revenue: $56M
EBIT: $194M
Net Income: $162M